In a regulatory filing, Establishment Labs disclosed that On April 2, during the J.P. Morgan MedTech 2024 CEO Conference Call Series, the company is announcing that the FDA has scheduled the PMA preapproval inspection of the company’s manufacturing facility for Motiva Implants. The inspection by the FDA is scheduled to take place during Q2 of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs price target raised to $65 from $50 at Mizuho
- Establishment Labs price target raised to $60 from $50 at TD Cowen
- New Regulation Risk for Establishment Labs Holdings – What’s the Latest?
- Establishment Labs price target raised to $49 from $32 at Citi
- Establishment Labs price target raised to $53 from $45 at BTIG
